ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in ...

Based on its selective targeting of toxic Aβ oligomers and the ... misfolding-specific monoclonal antibodies and intrabodies against a pathogenic loss-of-structure epitope in the N-terminal ...

Note: Among the 20 tested antibodies, 1E4E11, 5H11C10, 2-48, Aβ-pE3, and Donanemab bs have known PTM-selectivity ... In contrast, the crystal structure (PDB 6CO3) harbors a sulfate ion that ...

Researchers used AI models to design antibodies that neutralize over 1,300 SARS-CoV-2 strains, including Delta and Omicron.

"The decrease in motivation to implement lifestyle changes after the disclosure of elevated or nonelevated Aβ status warns against false reassurance during the disclosure process." HealthDay News ...

Some practitioners argue that method of treatment claims are easier to obtain for structure–function-defined antibodies, but recent USPTO prosecution histories show that these claims also face ...

Cancer scientists engineer a new type of antibody which could be used to boost the immune systems of patients fighting disease.

CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody ...